- Home
- ALDX
as 05-20-2024 1:34pm EST
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 243.0M | IPO Year: | 2014 |
| Target Price: | $9.33 | AVG Volume (30 days): | 569.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $11.97 | Next Earning Date: | 05-02-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 29.92% |
Share on Social Networks:
Stock Insider Trading Activity of Aldeyra Therapeutics Inc. (ALDX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | ALDX | 10% Owner | Apr 4 '24 | Buy | $4.67 | 140,281 | $655,112.27 | 9,238,139 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ALDX | 10% Owner | Apr 4 '24 | Buy | $4.74 | 37,712 | $178,754.88 | 9,275,851 | SEC Form 4 |
| Greenberg Bruce | ALDX | See Remarks | Mar 11 '24 | Sell | $3.41 | 13,201 | $44,967.89 | 130,154 | SEC Form 4 |
| Machatha Stephen | ALDX | Chief Development Officer | Mar 9 '24 | Sell | $3.16 | 11,537 | $36,503.07 | 243,495 | SEC Form 4 |
| Machatha Stephen | ALDX | Chief Development Officer | Mar 9 '24 | Sell | $3.41 | 18,231 | $62,102.08 | 255,032 | SEC Form 4 |
| Greenberg Bruce | ALDX | See Remarks | Mar 9 '24 | Sell | $3.41 | 13,201 | $44,967.89 | 120,699 | SEC Form 4 |
Latest Aldeyra Therapeutics Inc. News
ALDX Breaking Stock News: Dive into ALDX Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
MT Newswires
12 days ago
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study
Business Wire
12 days ago
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Business Wire
25 days ago
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Zacks
a month ago
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Business Wire
a month ago
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Zacks
a month ago
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Zacks
a month ago